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Abstract: Nitric oxide (NO) is a free radical and a signaling molecule in several pathways, 
produced by nitric oxide synthase (NOS) from the conversion of L-arginine to citrulline. 
Supplementation of L-arginine has been used to treat MELAS (mitochondrial 
encephalopathy with lactic acidosis and stroke like syndrome), a mitochondrial disease 
caused by the m.3243A>G mutation. Low levels of serum arginine and endothelium 
dysfunction have been reported in MELAS and this treatment may increase NO in 
endothelial cells and promote vasodilation, decreasing cerebral ischemia and strokes. 
Although clinical benefits have been reported, little is known about NO synthesis in 
MELAS. In this study we found that osteosarcoma derived cybrid cells with high levels of 
m.3243A>G had increased nitrite, an NO metabolite, and increased intracellular NO, 
demonstrated by an NO fluorescent probe (DAF-FM). Muscle vessels from patients with 
the same mutation had increased staining in NADPH diaphorase, suggestive of increased 
NOS. These results indicate increased production of NO in cells harboring the 
m.3243A>G, however no nitrated protein was detected by Western blotting. Further studies 
are necessary to clarify the exact mechanisms of L-arginine effect to determine the 
appropriate clinical use of this drug therapy. 
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1. Introduction 
Nitric oxide (NO) is involved in the regulation of several pathways such as mitochondrial 
respiration, mitochondrial biogenesis and apoptosis, while it also can act as a free radical and cause 
oxidative damage. NO is produced by the isoenzyme nitric oxide synthase (NOS) which consumes  
L-arginine, producing NO and L-citrulline [1]. There are three isoforms of NOS: neuronal NOS (nNOS), 
endothelial NOS (eNOS) and inducible NOS (iNOS). The neuronal and endothelium forms are 
constitutive, but despite their denominations, they have also been identified in several other tissues. 
Both are activated by high levels of Ca2+ and requires the interaction between Ca2+ and calmodulin [1]. 
The iNOS is only activated during inflammatory or defense responses, is not dependent on  
Ca2+-calmodulin interaction and it is mainly expressed in macrophages [2]. In the brain, iNOS is 
induced in microglia and astrocytes by the presence of pathogens, brain damage or hypoxia [3]. 
Mitochondrial diseases are characterized by genetic defects leading to respiratory chain enzyme 
deficiency, with extremely variable clinical phenotypes, ranging from exercise intolerance to severe 
infantile encephaloneuromyopathies [4,5]. Until now, there is no effective pharmacological treatment 
for mitochondrial diseases [6]. One of the most devastating phenotypes of mitochondrial diseases is 
MELAS, mitochondrial encephalopathy with lactic acidosis and stroke like syndrome, which affects 
children and adults, with episodes that are very similar to strokes. MELAS is a very incapacitating 
disease because stroke-like episodes occur repeatedly, with progressive neurological deficits, including 
cortical blindness, convulsion and hemiparesis. In the majority of the cases, MELAS is caused by a 
mitochondrial DNA (mtDNA) mutation, m.3243A>G, in the tRNALeu(UUR) gene, present in high levels 
in the affected tissues [7,8]. Muscle biopsy shows fibers with intense mitochondrial proliferation, 
called ragged red fibers (RRF), typically found in mitochondrial disorders. The same mitochondrial 
proliferation is also found in smooth muscle blood vessels in skeletal muscle biopsies, seen as vessels 
surrounded by intense blue on succinate dehydrogense (SDH) histochemistry, which are known as 
SSV, strong SDH-reactive blood vessels [9]. SDH and cytochrome c oxidase (COX) histochemical 
staining are largely used in the evaluation of mitochondrial function in muscle biopsies [6]. Because 
SDH is totally encoded by nuclear genes, it is not affected in mitochondrial diseases due to an mtDNA 
mutation. COX histochemistry is also very helpful, because it is frequently affected in patients with 
mtDNA mutations, with a pattern of focal COX deficiency, characterized by isolated and scattered 
muscle fibers with partial or total COX deficiency. 
The pathogenesis of the stroke-like episode is still not clear. It could just be a manifestation of the 
cellular metabolic deficit or due to a deficiency in smooth muscle vascular relaxation, causing 
vasoconstriction and ischemia. Recently a Japanese group proposed a new therapy for MELAS based 
on reposition of L-arginine [10]. Their results are very promising when we consider clinical 
improvement because the patients had reduced frequency of stroke like episodes after short and long 
term administration of L-arginine [11]. However, the mechanism by which L-arginine acts is not 
understood. The basic concept for this treatment was the fact that previous studies demonstrated low 
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levels of serum arginine [11] and endothelium dysfunction [9] in patients with MELAS. One of the 
functions of NO is to promote smooth muscle cell relaxation and vasodilation, so L-arginine would 
promote vasodilation in cerebral small vessels, which would improve neurological deficits in  
MELAS [12]. However little is known about basal NO synthesis in MELAS. 
In this study, we aimed to evaluate NO synthesis in cells with the m.3243A>G mutation. We found 
that NO levels were increased in these cells and that NOS activity was not reduced in muscle vessels 
from patients with this mutation. Although increased levels of NO were found, no nitrated proteins 
were detected. 
2. Results and Discussion 
To study changes in NO synthesis related to MELAS mutation, we used transmitochondrial cybrid 
lines. Cybrid cells were derived from human osteosarcoma cell lines devoid of mtDNA, which were 
fused with enucleated cells containing mtDNA from patients [13]. They are very useful to study the 
effects of a specific mtDNA mutation, especially when using homoplasmic cells (containing 100% 
mutated mtDNA) in comparison with cells harboring 100% normal mtDNA (143B). The evaluation of 
the effect of a mutated mtDNA in tissue samples, such as muscle, is more difficult because the 
proportion of mutated molecules is variable in different cells. For this reason, we used cybrid cells 
with high level (93%) of the m.3243A>G mutation to verify the influence of this mutation on NO 
production. Although it would be ideal to use cybrid cells with 100% mutant mtDNA, the use of cells 
with a high level of mutant mtDNA, such as those used in this study, is also valid as far as they retain 
the phenotypic features caused by the mutation. We confirmed that cultured cells used in the 
experiments, retained their original features by checking the genotype and by confirming the decreased 
activities in complexes I, III and IV respiratory chain enzymes by spetrophotometric assays (Table 1). 
We also confirmed that mtDNA content was not altered in cybrid cells with the m.3243A>G compared 
to 143B cells (Figure 1). 
Table 1. Respiratory chain enzyme activities by spectrophotometry. 
Cell type 
C-I 
(nmol/mg/min) 
C-II 
(nmol/mg/min) 
C-II+III 
(nmol/mg/min) 
C-IV 
(nmol/mg/min) 
CS 
(nmol/mg/min) 
143B 158.11 109.68 70.68 78.53 16.54 
m.3243A>G 18.48 112.82 31.41 29.84 32.35 
Notes: C-I = complex I; C-II = complex II; C-II+III = complex II + III; C-IV = complex IV; CS = citrate synthase. 
Because NO is a gaseous molecule with short half-life, direct NO detection and quantification is 
very difficult. Nitrite (NO2−) and nitrate (NO3−) are stable metabolites of NO and can be easily 
measured in body fluids, so the determination of nitrite is an indirect method but frequently used to 
evaluate NO production [14]. Our results showed that cells with m.3243A>G had a significant increase 
in the mean value of nitrite content (10.55 µg of nitrite per microgram protein) while 143B cells had only 
0.68 µg of nitrite per µg protein (Figure 2). 
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Figure 1. Evaluation of mtDNA content: (a) Polymerase chain reaction (PCR) products 
representative of an mtDNA segment and a nuclear gene (nuclear DNA, nDNA) are shown 
after 25, 30 and 35 cycles in a 2% agarose gel; (b) The intensity of the bands are expressed 
as optical density and are demonstrated in the graphs, showing the mtDNA bands (full line) 
and nDNA bands (dotted line). The graphs show that the interpolated curves obtained from 
the mtDNA have an exponential nature; (c) Using the log of optical densities, the 
relationship with number of cycles is linear for all parameters (mtDNA, nDNA, 143B and 
m.3243A>G), making the data comparable among different time points; (d) An 
mtDNA/nDNA ratio was obtained using the transformed results. The graph shows that the 
linear regressions obtained from 143B and m.3243A>G cells have similar slopes and 
intercepts, demonstrating that mtDNA content is similar in both cell lines. M = 100 bp ladder. 
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Figure 2. High nitrite content in cybrid cells with the m.3243A>G mutation. Cells with 
m.3243A>G showed a significant higher nitrite content (* p = 0.007) than 143B cells. 
Mann-Whitney test; number of samples =5; bars show means and standard deviation. 
 
To confirm that NO synthesis was increased, we used a fluorescent intracellular NO marker, DAF-FM 
(4-amino-5-methylamino-2',7'-difluorfluorescein), which produces fluorescence when reacts with NO. 
DAF-FM fluorescence signal was corrected to the number of viable cells using Hoechst dye (nuclear 
marker) fluorescence as a reference. We obtained a significant higher fluorescence (mean = 0.20) in cells 
with mutated mtDNA when compared to 143B cells (mean = 0.13). After treatment with  
L-NMMA (NG-monomethyl-L-arginine acetate salt), a NOS inhibitor, the fluorescence was 
significantly reduced in cells with m.3243A>G mutation (mean = 0.10), while in 143B cells the 
difference was not significant with a mean value of 0.09 (Figure 3). After L-NMMA treatment, 
fluorescence intensity was similar in both cells, which we considered as a background. Higher 
concentrations of L-NMMA were not able to abolish this background (not shown). The increased 
signal in cells with mutated mtDNA was totally inhibited by L-NMMA, showing that this fluorescence 
was originated from NO produced by NOS. 
Figure 3. DAF-FM intracellular fluorescence is increased in cybrid cells with m.3243A>G 
mutation. Fluorescence obtained in cells with m.3243A>G was significantly increased 
when compared to the wild type (143B cell). Cells with mutated mtDNA had a significant 
decrease in fluorescence after treatment with L-NMMA, showing that NO detected by this 
probe was produced by NOS. * p = 0.05, Mann-Whitney test, number of samples =3, red 
horizontal lines = means. 
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Because our results suggested higher levels of NO production in mutant cybrid cells, a Western blot 
analysis with an antibody against nitro-tyrosine was performed to evaluate the level of protein 
nitration. In this experiment, we could not detect any bands with this antibody using up to 200 µg of 
cell lysate protein (Figure 4). The specificity of the antibody was confirmed by the detection of nitrated 
albumine (positive control). The integrity of the proteins was confirmed by staining the membrane 
with Coomassie blue and obtaining the correct bands of other mitochondrial proteins, porin 
(mitochondrial membrane protein) and SDH-Fp (flavoprotein subunit of SDH). 
Figure 4. Detection of nitrated protein by Western blotting. (a) Incubation with  
anti-nitrotyrosine antibody showed the nitrated abumine (positive control), demonstrating 
that the antibody was specific. No nitrated protein was detected in samples from 143B and 
m.3243A>G cybrids, with 20 and 30 µg protein/lane. (b) Protein integrity was confirmed 
by the detection of the bands corresponding to SDH-Fp and (c) porin. 
 
(a) 
 
(b) 
 
(c) 
Because MELAS is a mitochondrial disease with vascular involvement, we investigated NADPH 
(dihydronicotinamide adenine dinucleotide phosphate dehydrogenase) diaphorase (NADPHd) activity 
in small arterial vessels seen on muscle biopsies of patients with m.3243A>G mutation. NADPHd is a 
histochemical reaction used as an indirect method for detection of NOS activity. Muscle biopsies are 
the most available tissues to evaluate small vessels in these patients because most of the patients with a 
mitochondrial disease, have a muscle biopsy as part of the diagnostic investigation. We selected 
vessels from muscle biopsies of three patients with m.3243A>G mutation and compared to three 
controls (Table 2). The control samples were selected among diagnostic muscle biopsies and showed 
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normal pattern of morphology and histochemistry, while clinical diagnosis were not related to 
mitochondrial diseases (Table 2). 
Table 2. Patients used for the study of muscle small vessels. 
Patient Age at biopsy Clinical diagnosis Muscle biopsy m.A3243A>G (%) Number of vessels
1 45 exercise intolerance, 
myopathy 
RRF, COX+ 56 1 
2 19 MELAS RRF, COX+ 67 1 
3 4 MELAS RRF, COX+ 46 1 
4 31 fatigue normal absent 3 
5 23 fatigue normal absent 1 
6 43 non-specific dermatitis normal absent 1 
Quantitative analyses of histological staining of skeletal muscle vessels confirmed the increased 
mitochondrial content in patients with m.3243A>G mutation (mean = 1.09), with statistically 
significant increase in SDH staining in the vessels when compared to controls (mean = 0.88), typically 
found in SSV (Figure 5). A similar increase in NADPHd staining was also observed in SSV (mean in 
patients = 3.42, mean in controls = 1.31), suggesting that an increase in NOS activity or content of the 
enzyme. COX staining was not statistically significant (mean in patients = 1.38; mean in controls = 1.28) 
and did not increase proportionally to the SDH staining, suggesting a partial COX deficiency in 
skeletal muscle vessels. 
Figure 5. NADPHd in skeletal muscle vessels. (a) SSV and control vessel stained after 
histochemistry for SDH, NADPHd and COX; (b) Quantification of histochemistry staining 
in muscular vessels demonstrated that patients had a significant increase in SDH staining, 
confirming the mitochondrial proliferation in the vascular wall. NADPHd staining was also 
significantly increased in patients. However there was no increase in COX staining.  
* p = 0.036, Mann-Whitney test; red horizontal lines = mean; scale bar = 20 µm. 
 
(a) 
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Figure 5. Cont. 
 
(b) 
The exact mechanism of stroke like episodes in MELAS is still unknown. There are mainly three 
hypotheses for the cause these episodes: (a) Angiopathy, leading to a decrease in arterial relaxation and 
hypoperfusion; (b) Cytopathy, causing a mitochondrial dysfunction and neural damage; (c) Neuronal 
hyperexcitability, due to imbalance between energy supply and demand [15]. L-arginine 
supplementation is a promising therapy for MELAS [9–11,16]. An improvement of neurological 
deficits in the acute phase and a decrease in the frequency of stroke like episodes with prolonged oral 
supplementation of L-arginine has been reported [9–11,16]. L-arginine treatment rationale is based 
mainly on the fact that patients with MELAS have decreased plasma levels of arginine [17,18], which 
is considered an NO precursor, leading to a deficiency in endothelium dependent vascular relaxation [18]. 
Using isotope infusion techniques, El-Hattab et al. found that whole body NO synthesis rate was low 
in patients with MELAS and increased after supplementation of arginine and citrulline [17]. This 
finding is interesting, but it is difficult to interpret considering that NOS are expressed in several 
tissues and the result is not tissue specific. 
It is believed that NO deficiency may be caused by multiple factors: (a) Endothelial dysfunction;  
(b) NO sequestration by COX in COX-positive sites; (c) NO shunting into reactive nitrogen species 
formation; (d) Decreased availability of NO precursors (arginine and citrulline); (e) Increased 
asymmetrical dimethy-larginine (ADMA) concentration, an NOS endogenous inhibitor [19,20]. 
Vascular abnormalities are supported by observations of SSV and vasogenic edema in stroke-like 
episodes [18]. Because COX activity is present in SSV in patients with MELAS, it is hypothesized that 
COX hyperactivity may decrease regional NO concentration, leading to a segmental vasodilation defect 
especially in the segment of SSV regions in cerebral artery or arterioles [20]. Although SSV had COX 
activity in muscle vessels, we did not find increased activity in muscle vessels in patients in this study. 
NO synthesis may also be decreased due to increased levels of ADMA (asymmetrical dimetyl-arginine) 
and free radicals [18,19], which is supported by the finding of high levels of plasma concentration of 
ADMA in patients with MELAS [17]. 
Our results are not in agreement with the hypothesis of low NO synthesis, showing an opposite 
scenario. When analyzing NADPHd staining in SSV, we observed increased staining, suggestive of 
increase of NOS activity or expression. NADPHd is an indirect marker of NOS activity but with good 
correlation between NOS expression and NADPHd staining [21–23]. The specificity of this staining as 
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an NOS activity indicator is a result of the use of Triton-X in the incubation medium, that enhances 
formazan generated by NOS related NADPHd [21]. Our results are supported by the finding of 
increased expression of eNOS in muscle blood vessels of patients with MELAS, while iNOS was not 
expressed in the same vessels [24]. Furthermore, in our previous work, we also found increased NOS 
activity in muscle of patients with m.3243A>G mutation, seen as increased NADPHd activity in the 
sarcoplasm of muscle fibers with mitochondrial proliferation and COX activity [23]. Although NO 
synthesis was increased in cybrids with m.3243A>G mutation, we could not detect any nitrated 
proteins in homogenates from cybrid cells by immunoblotting. Vattemi et al. were able to detect 
nitrated proteins in muscle blood vessels by immunostaining and in muscle homogenates by two 
dimensional immunoblot patients with MELAS [24]. The discrepancy of these results can be explained 
by the fact that we searched for nitrated proteins in cybrids homogenates, a different cell type, which 
could have lower levels of nitrated proteins, below the detection limit of this method. We have not 
checked for nitrated proteins in muscle blood vessels, but our finding of increased activity of NADPHd 
is in agreement with the presence of nitrated protein in this tissue, as NO synthesis is probably increased. 
The comparison of our results with those from other studies showing decreased NO synthesis is 
difficult due to the diverse methods employed in each study [9,12,17]. Koga et al. [9,12] evaluated 
arginine and NO metabolites levels in plasma and urine of patients, which may not be good indicators 
of NO synthesis at the cellular level. Using an isotope infusion method, El Hattab et al. [17] also 
determined arginine, citrulline and NO metabolites in serum from patients, finding lower NO synthesis 
rate associated with reduced arginine and citrulline plasma concentration. Discrepant results are also 
found in other studies. Koga et al. [12] found reduced levels of NO metabolites in plasma and urine 
samples from patients in the acute phase while higher levels were observed in the inter-ictal phase. 
Vattemi et al. [24] could not find any differences in skeletal muscle NOS activity between controls and 
patients with mitochondrial disease by measuring (3H) L-arginine to (3H) L-citrulline conversion. 
However they found increased expression of eNOS in skeletal muscle homogenates of patients with 
mitochondrial diseases which supports our finding of increased NO synthesis in cybrid cells with the 
m.3243A>G mutation. Furthermore, in agreement with what was seen by Koga et al. [12] , it is 
possible that we found higher values of NO synthesis due to the clinical phase, as the patients were not 
in acute phase of a stroke like episode. 
Arginine and its metabolite products have several physiological roles, such as: ammonia 
detoxification, signal transduction, neuronal Na-K ATPase activity, neurotransmitter release, calcium 
homeostasis, maintenance of membrane potential and ion gradients, inhibition of cell proliferation and 
inhibition of NOS [25]. The regulation of arginine metabolism and mechanisms of its complex 
physiological roles still need clarification. Recently, Yoneda et al. [15] proposed that a second 
mechanism for the therapeutic effect of L-arginine is an acceleration of the tricarboxilic cycle (TCA) 
cycle. This hypothesis is based on the observation of a severe suppression of the TCA cycle metabolic 
rate in hearts of patients with mitochondrial cardiomyopathy, indicating a shift in energy production to 
the anaerobic pathway. L-arginine treatment was able to enhance the TCA cycle in these patients [26]. 
The basal levels of arginine in mutant cells and the direct effect of L-arginine supplementation on 
cybrid cells with the m.3243A>G mutation are interesting points that need further investigation. A 
recent study using cybrid cells derived from neuroblastoma cell line showed that cells with the 
m.3243A>G improved complex I activity with the addition of L-arginine in the culture medium [27]. 
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In the same study, lower nitrite concentration was found in supernatant of mutant cells, suggesting that 
NO was decreased in these cells. Although we used the same method to determine nitrite content, our 
results are still difficult to compare, first, because there may be differences regarding the cell type as 
we used cybrids derived from osteosarcoma cell line, and second, because in our study we corrected 
the value of nitrite content to the total amount of protein in the plate, which was not done by 
Desquiret-Dumas et al. [27]. In another study, El-Hattab et al. [17] showed that citrulline 
supplementation had a greater efficacy in increasing NO production when compared to arginine 
supplementation, promoting a marked increase in the de novo arginine synthesis. 
Because L-arginine therapy is not free of side effects [18,28,29], it is important to clarify the exact 
mechanisms of L-arginine improvement to determine the potential implications regarding benefits, 
dosage and side effects. Several issues need more clarification. We show that NO synthesis is 
increased in cells with the MELAS mutation, but we still do not know the exact role of this increase at 
the cellular or mitochondrial level. We can think in several possibilities. NO could have a protective 
role, acting in signaling for mitochondrial proliferation [30]; improving the blood flow and substrates 
supply to mitochondria or participating in redox signaling events [31]. On the other hand, increased 
NO can inhibit mitochondrial respiration and generate peroxynitrite, inducing nitrosative stress [32]. 
The NO roles on several signaling pathways are very complex and can be different depending on the 
cell type and intracellular location of NO synthesis. Further studies are still needed to clarify all those 
issues and discrepancies found in different studies but the knowledge of the basal levels of NO 
synthesis in mitochondrial deficient cells are crucial to a better understanding of L-arginine therapy. 
L-arginine supplementation as a therapeutic approach is based on the assumption that there is an NO 
deficiency or that L-arginine will promote increase in NO synthesis and consequent vasodilation, 
improving the cerebral vascular blood supply. However, we show that NO synthesis is increased in 
cells with m.3243A>G mutation, which suggests another mechanism for the effects of L-arginine therapy. 
3. Experimental Section 
3.1. Cell Culture 
Osteosarcoma derived cells with wild type mtDNA (143B) and the mutation m.3243A>G were used 
in this study. Cybrid cells were obtained from fibroblast cells of a patient with the 3243A>G mutation. 
Cells were grown at 37 °C with 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) with high 
glucose (4,500 mg/L D-glucose) and 4 mM L-glutamine (Gibco BRL: Carlsbad, CA, USA), 
supplemented with 44 mM sodium bicarbonate (Sigma: Taufkierchen, Germany), 15% Fetal Bovine 
Serum (FBS), minimum essential media (MEM) vitamin solution, 10 mM MEM non-essential aminoacids 
solution, 100mM sodium pyruvate, penicillin (100 U/mL), streptomycin sulfate (100 μg/mL), 
fungizone (0.5 μg/mL) (all from Gibco BRL) and uridine (100 μg/mL) (Sigma). 
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3.2. Cell lines Characterization 
3.2.1. Genotyping 
Detection of the 3243A>G mutation was performed by restriction fragment length polymorphism 
(RFLP) analysis with ApaI. We amplified a 293 bp fragment encompassing the 3243 position, using 
the following primers: forward (aggacaagagaaataaggcc) and reverse (tacgcaaaggccccaacgtt). Digestion 
with ApaI was performed at 37 °C for two hours, followed by separation in 1% agarose gel stained 
with ethidium bromide. The presence of the m.3243A>G mutation creates one site for ApaI, resulting 
in two bands (177 bp, 116 bp). Normal mtDNA does not have the restriction site and would not be cut. 
The percentage of mutated mtDNA was estimated by quantification of the intensity of the bands. 
3.2.2. Evaluation of mtDNA Content by Semi-Quantitative PCR 
We performed the PCR amplification of two regions representing the mtDNA and nDNA. The 
mtDNA region was amplified using two primers (forward: 5'-aggacaagagaaataaggcc-3'; reverse:  
5'-tacgcaaaggccccaacgtt-3') encompassing the region between nucleotides 3130 and 3423). A segment 
containing exon 5 of the nuclear gene NDUFV1 (a complex I subunit) was amplified using the primers: 
forward 5'-gctgggaaactcacaccttt-3' and reverse 5'-caaagggagcctagccagat-3'. Total DNA was quantified 
using Hoechst dye as DNA fluorescent probe in the Versa Fluor fluorometer (Bio-Rad). PCR reaction 
was performed with 30 ng of total DNA, PCR buffer (Fermentas), 2.5 mM MgCl2, 20 nmol of each 
dNTP (deoxyribonucleotide triphosphates), 20 pmol of each primer and 2.5 units of Taq DNA 
polymerase (Fermentas). PCR conditions were: initial denaturing step at 94 °C for 2 min, followed by 
35, 30 or 25 cycles with 94 °C (30 s) and 60 °C (30 s) and a final extension step at 72 °C for 10 min. 
PCR products were electrophoresed through a 2% agarose gel and photographed under UV light. The 
bands were quantitated by densitometry using the Image J 1.43r Software. The results were plotted 
against number of cycles and the ratio mtDNA/nDNA was obtained using the log of optical density of 
the bands obtained with 25, 30 and 35 cycles. 
3.2.3. Biochemical Enzyme Assays 
3.2.3.1. Isolation of Mitochondria 
Biochemical enzyme assays were performed with mitochondrial enriched fractions obtained from  
4 × 106 cells [33], resuspended in 400 µL of mannitol buffer (225 mM mannitol, 75 mM sucrose, 10 mM 
Tris-HCl, 0.1 mM ethylenediamine tetraacetic acid, pH 7.2) [34] and homogenized in a hand-held 
Potter Elvehjem homogenizer in ice. The homogenates were centrifuged (600g, 4 °C, 10 min) and 
supernatant was transferred to another tube. A second step of homogenization of the same pellet was 
performed as above and then added to the first tube. Supernatants were centrifuged (15,000g, 4 °C,  
10 min) to precipitate mitochondria. Pellets were resuspended in mannitol buffer and protein 
quantification was performed with the BCA Protein Assay kit (Pierce®). Adequacy of mitochondrial 
fraction was confirmed by the absence of a cytoplasmic enzyme activity, lactate dehydrogenase  
(EC 1.1.1.27) [35], and easy detection of other respiratory chain enzymes and citrate synthase  
(EC 4.1.3.7) activities [36]. 
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3.2.3.2. Complex I (NADH ubiquinone oxido-reductase, EC 1.6.5.3) 
Immediately before the assay, mitochondria (20 µL, 1 µg/µL) were permeabilized with two cycles 
of freeze/thawing: Freezing in alcohol with dry ice and thawing at 37 °C. C-I assay [37] was 
performed in the Cary 50 spectrophotometer (Varian Inc.: Victoria, Australia) with readings during  
6 min. We followed the oxidation of NADH to NAD+ (NADH extinction coefficient = 4.87) at  
340 nm with 380 nm as the reference wavelength. The assay was performed at 37 °C, in an 1 mL 
cuvette with 25 mM K2HPO4 (pH 7.4), 5 mM MgCl2, 0.25% bovine serum albumin, 3.7 µM  
antimycin A, 2 mM KCN, 16% dimethyl sulfoxide, 40 mM reduced NADH. The reaction was started 
with the addition of the acceptor, ubiquinone 1, in the final concentration of 100 µM [37]. Extinction 
coefficient = 4.87 mM−1cm−1. 
3.2.3.3. Complex II (Succinate Decylubiquinone DCPIP Reductase, EC 1.10.2.2) 
The assay was performed at 600 nm following the decrease in absorbance resulting from the 
reduction of 2,6-dichlorophenolindo-phenol (DCPIP). In 1 mL of medium (10 mM KH2PO4, pH 7.8,  
2 mM EDTA, 1 mg/mL bovine serum albumin, BSA) we added 30 µg of mitochondria, 80 µM DCPIP, 
4 µM rotenone, 0.2 mM ATP and 10 mM succinate. The mix was incubated for 10 min at 30 °C and 
the reaction started with the addition of 80 µM decylubiquinone and inhibited with 1 mM 
tenoiltrifluoracetone (TTFA) [38]. Extinction coefficient = 19.1 mM−1cm−1. 
3.2.3.4. Complex II + III (Succinate Cytochrome c Reductase, EC 1.3.5.1 + EC 1.10.2.2) 
The assay was performed at 550 cm following the increase in absorbance resulting from the 
reduction of cytochrome c. In 1 mL of medium (25 mM KH2PO4, pH 7.2) we added 30 µg of 
mitochondria, 240 µM KCN, 4 µM rotenone and 20 mM succinate. The mix was incubated for 10 min 
at 30 °C and the reaction was started with the addition of 40 µM oxidized cytochrome c and inhibited 
with 1 mM tenoiltrifluoracetone [38]. Extinction coefficient = 19.1 mM−1cm−1. 
3.2.3.5. Complex IV (Cytochrome c Oxidase, EC 1.9.3.1) 
The assay was performed at 550 nm following the decrease in absorbance resulting from the 
oxidation of reduced cytochrome c. In 1 mL of medium (10 mM KH2PO4, pH 6.5, 0.25 M sucrose,  
1 mg/mL BSA) we added 30 µg of mitochondria and 10 µM reduced cytochrome c. We followed the 
reaction for 3 min and then added 2.5 mM lauryl maltoside. The reaction was inhibited by 240 µM 
KCN [38]. Extinction coefficient = 19.1 mM−1cm−1 
3.2.3.6. Citrate Synthase 
Citrate synthase. The assay was performed at 412 nm following the reduction of 0.1mM  
5,50-dithiobis (2-nitrobenzoic acid) in the presence of 30 µg of mitochondria, 0.2 mM acetyl-CoA in a 
medium with 10 mM Tris-HCl, pH 7.5 and 0.2% Triton X-100. The mix was incubated at 30 °C for  
5 min and the reaction started with the addition of oxalacetic acid to a final concentration of 5mM [38]. 
Extinction coefficient = 13.6 mM−1cm−1. 
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3.3. Quantification of Nitrite 
Nitrite content was determined in culture medium by a diazotation assay with the Griess reagent 
(Molecular Probes: Location, Country) and spectrophotometric detection [39]. Cells were grown until 
90% confluence in 60 × 15 mm Petri dishes (TPP). After 72 h with no medium change, we incubated 
300 μL of culture medium with equal volume of Griess reagent [40]. Nitrite content was determined 
according to a standard curve obtained from samples containing known concentrations of sodium 
nitrite and corrected by total protein content (μg of nitrite per μg protein). Cell pellets from each dish were 
homogenized in 10% sodium dodecil sulfate (SDS), 10 mM ethylenediamine tetraacetic acid, 6% glycerol, 
10 mM ethylene glycol tetraacetic acid, 63 mM Tris (pH 6.8) and 50 mM dithiothreitol. Total protein was 
measured using the NanoOrange Reagent (Molecular Probes) according to manufacturer’s protocol. 
3.4. Quantitative Analysis of Intracellular NO 
DAF-FM diacetate (Molecular Probes), a cell membrane permeable probe, was used to detect 
intracellular NO. Once inside the cells, DAF-FM diacetate is deacetylated by intracellular esterases, 
becoming DAF-FM, which can be detected by fluorescent methods [41]. We plated 3 × 104 cells in  
12-well plates in DMEM high glucose, 10% FBS but with no phenol-red to avoid fluorescence 
interferences. The next day, the culture medium was replaced by DMEM high glucose without phenol-red 
and without FBS. After 24 h, with 90% confluence, cells were washed with DMEM without phenol-red 
or FBS and incubated with 5 μM DAF-FM diacetate at 37 °C with 5% CO2 for 1 h. Control samples 
were incubated with culture medium in the absence of DAF-FM diacetate. After incubation, cells were 
maintained for an additional 30 min in fresh medium to allow complete de-esterification of the 
intracellular diacetate. Then, cells were removed with TrypLE Express (Gibco BRL) and cell pellets 
were ressuspended in 1 mL DMEM high glucose without phenol-red or FBS. The fluorescence at  
495 nm (excitation) and 515 nm (emission) was determined in a fluorometer (Bio-Rad Versa Fluor™ 
Fluorometer) with 1 mL cuvette. Cells were also incubated with 1 μg/mL Hoechst dye-33258 
(Molecular Probes) for additional 15 min at room temperature and fluorescence was determined at 360 nm 
(excitation) and 460 nm (emission). Specificity of DAF-FM, as an NO probe, was checked by treating 
the cells with 1 mM L-NMMA (NOS inhibitor, Sigma) for 24 h. 
3.5. Detection of Nitrate Protein by Western Blotting 
We looked for nitrated proteins by performing a Western blotting analysis using an antibody against 
nitrotyrosine. Cell pellets were homogenized and 20–200 μg of total protein was run through a 12% 
denaturing polyacrylamide gel and electro-blotted to a 0.2 μm Sequi-Blot PVDF (polyvinylidene 
difluoride) membrane. After blocking with 5% milk in Tris-buffered saline Tween™-20 (TBS-T,  
20 mM Tris, 137 mM sodium chloride pH 7.6, 0.1% Tween™-20), the membrane was incubated with 
the primary antibodies (anti-nitrotyrosine, anti-SDH-Fp, and anti-porin) diluted in 1% milk in TBS-T, 
for 1 h at room temperature. Incubation with the secondary antibody (horseradish peroxidase 
conjugated antibody anti-rabbit IgG and anti-mouse IgG, 1:10,000 dilution) was performed for 1 h at 
room temperature and the bands were obtained through chemiluminescent detection with ECL System 
(Amersham Biosciences). 
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A positive control was obtained by overnight incubation of 6 mg/mL BSA (Sigma) in a solution 
with 10 mM sodium nitrite, 20 mM sodium acetate pH 5.6, 9 μM cupper chloride, 0.3% hydrogen 
peroxide at room temperature [42]. 
In order to verify the integrity of the proteins, the membrane was stained with 0.1% amido black in 
5% methanol and 10% acetic acid for 5 min. Primary antibody concentrations were: 1 μg/mL  
(anti-nitrotyrosine), 0.5 μg/mL (anti-SDH-Fp) and 2 μg/mL (anti-porin), all from Molecular Probes. 
3.6. Muscle Histochemistry 
We selected muscle biopsies from 3 patients with the m.3243A>G showing mitochondrial 
proliferation in skeletal muscle small vessels (SSV). Three muscle biopsies with no abnormalities and 
from patients with no clinical evidence of mitochondrial or metabolic myopathy were used as controls. 
We specifically analyzed arterial vessels seen on muscle biopsies after histochemical reactions for 
COX, SDH and NADPHd. Specificity of this staining was studied previously and certified by the  
co-localization of NOS expression and NADPHd staining [21,22]. 
3.7. Quantification of NOS Activity in Muscle Vessels 
Microscope images containing muscle vessels were obtained through a 20× objective, with the 
same luminosity and in serial sections with NADPHd, COX and SDH histochemistry. All images were 
placed in one archive, with no alteration in size and as JPEG format (150 pixels/inch). The analyses 
were performed using Image J software (1.43r); RGB images were converted to 8 bits color, with scale 
from 0 to 256. With the Brush tool, we selected the whole vessel wall and performed the 
measurements. Measurements were normalized using the measure obtained in one type II fiber of the 
same section, in order to allow comparability of all samples. 
3.8. Statistical Analysis 
Statistical analyses were performed using Prism 6 for MacOS X (GraphPad Software Inc.: La Jolla, 
CA, USA). Comparisons were done with the Mann Whitney test. Statistical significance was set to  
p ≤ 0.05. 
4. Conclusions 
This study shows that NO production is increased in cybrid cells with the mutation m.3243A>G but 
did not show any evidence of nitration of proteins. Muscle vessels had increased NADPHd activity 
suggesting that NOS activity is high in these cells. These results indicate that L-arginine therapy may 
be acting by other mode of action that does not involve a vasodilation defect due to decreased NO. 
Further studies must be performed to clarify the exact mechanisms of L-arginine effect to determine 
the appropriate clinical use of this drug therapy. 
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